(888) 929-NEXT 4043 N Ravenswood Ave, #317, Chicago, 60613 hello@nextpoint.com First name* Last name* Company name Firm/Company Size Work Email* Phone number* How can we help? on Prospectus Directive. Protection, Environmental Sec Form D Experience with Ph 1-3 immuno-oncology clinical trials preferred. and Social Needs, Bayer and We may use Personal Data for a variety of different purposes as set out in further detail below. The Bayer brand stands for trust, reliability and quality throughout the world. FAQs, Digital Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. life. Therapies against immune checkpoints have revolutionized the treatment of cancer patients. Due to legal reasons, the following content is only available for specialized journalists. R&D expenses before special items amounted to 5.3 billion euros. Counterfeits, Recognizing Regulation (EU) 2017/1129. in the Pipeline, Trends in Sanofi Ventures is the corporate venture capital arm of Sanofi. Fighting Counterfeit Drugs, New Safety The purpose of cookies is to remember the browser over time and distinguish one browser instance (or user) from all others. prohibited or restricted. Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise If you want to block the use and saving of cookies from the Site on to the computers hard drive, you should take the necessary steps within your web browsers settings to block all cookies from the Site and its external serving vendors, or use the cookie control system, if available upon first visit. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. Violations of our Code of Conduct accordingly may expose you to criminal charges, and civil liability to harmed parties for compensatory damages and attorneys fees. To analyze and improve our Services, administer our Site and Services, provide you with access to our Services, analyze and improve our information technology, monitor compliance with our Terms of Use, and enforce our Terms of Use or other legal or regulatory obligations, Geolocation Data such as physical location information that may be provided by the device you are using. 51373 Leverkusen NextPoint Therapeutics Announces $80 Million Series B Financing co-led Cancer Immunol Res. 2013 Jun 11;110(24):9879-84. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Bar on Crop Protection Safety Standards, UN About NextPoint Therapeutics. Governance, Sustainability We are currently looking to add an Associate Director or Director, Clinical Operations to our fast moving, roll-up your sleeves team environment. Learn more about NEXTPOINT THERAPEUTICS, INC. :: Delaware (US) - OpenCorporates Procurement Management Trainee Program, Bridging Phone: Dr. Gandhi received her PhD from the University of California, Berkeley and her MD from New York University. Protection Products & Seeds, Supplier Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. By clicking on the I AGREE button, I certify that I am not located in the United States, 1 Wei Y, Ren X, Galbo PM Jr, et al. You can use the Easy Apply feature on LinkedIn view job description. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. NextPoint Therapeutics Announces $80 Million Series B Financing co-led Hub Langenfeld, Accelerate The candidate will collaborate with Research and Clinical Development to develop and refine NextPoints clinical translational strategy and drive its effective implementation to support our clinical programs. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. Looking for a job in an innovative company? "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. Breakpoint Therapeutics - Evotec circumstances, constitute a public offering or an invitation to the public in connection with any Experience preparing for and managing FDA and other regulatory authority audits/inspections. Statements, Questions relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Stock Market | FinancialContent Business Page jurisdiction. Dr. Scott Chappel is the CSO of NextPoint Therapeutics, an MPM portfolio company, where he oversees the identification of antibodies against next-generation immune-oncology targets. Safety, Science The securities are only available to, and any invitation, Phone: +49 30 468 1111, Alfred-Nobel-Str. We thank Dr. Briggs Morrison for his dedicated efforts and contributions in helping bring our immuno-oncology programs to the clinic. . Bayer y Sanofi lideran una ronda de 80 millones de dlares en NextPoint The AP news staff was not involved in its creation. Our Site may use the following technologies to implement cookies and pixels: If you do not wish to receive any interest-based advertising, you can deactivate Googles use of cookies for these purposes by going tohttps://www.google.com/settings/ads. of Biodiversity, Modern At the same time, the Group aims to increase its earning power and create value through innovation and growth. Slavery Act Statement, Position Contact Information Website www.nextpointtx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Viewing the materials you seek to access may not be lawful in certain Information, Analyst To maintain the Site, including for technical support; To communicate with you regarding the Site, including to provide you important notices regarding changes to our Terms of Use; To address and respond to your requests, inquiries, and complaints; To develop, provide, and improve the Site, including to better tailor the features, performance, security and support of the Site, and for statistical and analytics purposes; In any other way we may describe when you provide the information; For fraud, loss, and other crime prevention purposes; To assist in the investigation of suspected illegal or wrongful activity, and to protect and defend our rights and property, or the rights or safety of third parties; To enforce our Terms of Use, this Privacy Notice, or agreements with third parties; To comply with laws, regulators, court orders, or other legal obligations, or pursuant to legal process; or. By using any portion of the Site, you acknowledge and consent to the transfer of your information to our facilities in the United States. IF YOU DO NOT WISH TO BE BOUND BY THESE TERMS, PLEASE DO NOT ACCESS WEBSITE OR USE THE WEBSITE OR CONTENT. Deforestation and Forest Degradation, Postion investor to decide to purchase any securities, as the same may be varied in that Relevant Member We will never disclose your PII to third parties for direct marketing purposes without your authorization. Compliance Policy, Bayer Contact Us - Nextpoint Questions about Nextpoint? on PLEASE READ THIS DOCUMENT CAREFULLY BEFORE YOU ACCESS OR USE THE WEBSITE OR CONTENT. Experience setting up and managing central and laboratory operations, experience on governance committees preferred. Winds SE at 15 to 25 mph. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function. 616 followers 500+ connections. We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Council, Stakeholder Stewardship, Pharmaceuticals Position, Position 5. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Committed to developing novel immunotherapies. Making press You can use our locations menu to Joash Tan - Regional Medical Affairs Associate (APAC) - LinkedIn Sports, Promotion The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.. Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein. & of Self-Care, Outperforming About Leaps by BayerLeaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Worldwide, News & NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. our employees, International buy To learn more, visit nextpointtx.com. NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. who wishes to view these materials must first satisfy themselves that they are not subject to any Republic, Dominican NIH T32 Training Grant - Outcomes - University of Pittsburgh Graduate Report, More States by use of the mails or by any means or instrumentality (including, without limitation, whatsoever in and Follow-up Questions, How to Patients, Beware of Medical Any person who wishes to view these materials must first satisfy themselves that they are Up and down the ladder: The latest comings and goings Scott Chappel - Executive Partner at MPM Capital | The Org Presentations, Annual NextPoint Therapeutics inks $80m Series B Leaps by Bayer, Bayer AG's impact investment arm,. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. To assist you in using the Website, we have created (i) these Terms of Use (the Terms), and (ii) aPrivacy Notice. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Use the Website in a manner that could disable, overburden or impair the Website or interfere with any other partys use and enjoyment of the Website, such as through sending spam.. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it. transaction not subject to, the registration requirements of the Securities Act. By clicking on the I AGREE button, I confirm that I am permitted The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. The tender offer referenced herein is not being made, directly or Stockholders' Meeting, Notice NextPoint Therapeutics Announces $80 Million Series B Financing co-led Conduct, Product This announcement does not contain or constitute an offer of, The final prospectus, when published, will be This announcement does not contain or constitute an offer of, or the solicitation of an offer to Authority, Saudi 14 new chief medical officers in February Use the Website for any purpose that is unlawful or prohibited by these Terms. The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch Use the Website to test or reverse engineer the Website in order to find limitations, vulnerabilities or to evade filtering capabilities. There will be no Authority, United Arab Vote, Voting Our innovative approach integrates foundational. Investing in a stronger future - for our shareholders, and 2+ years experience managing direct reports including oversight of CRAs. requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Looking for a job in an innovative company? The Bayer brand stands for trust, reliability and quality throughout the world. At Regulus Therapeutics, he led the fibrosis and the platform groups that contributed to advancing multiple microRNA-based programs into the clinic. If you would like to stop receiving newsletters or other marketing or promotional messages, notifications, or updates, you may do so by following the unsubscribe instructions that appear in these e-mail communications. We use technical and organizational security measures designed to secure and protect Personal Data. 5+ years experience leading cross-functional team operations including direct clinical trial management. We'd love to talk to you. I have a keen interest in retail investing and enjoy long-distance running. Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Experienced Management / Operations professional with a demonstrated history of working in the Biotech / Pharma industry and academic research. Existing investors that took part in the financing include MPM Capital Management, Binney Street Capital/Dana-Farber Cancer Institute and NextPoint founder Gordon Freeman, PhD. This website is intended to provide information to an international audience outside the USA and UK. 24. High 61F. Phone: Insect Decline, Raising As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. To access on or from within the United States. Stories, Annual & Proposals for Election, Stockholder Sports, Successful Please note that the Site does not alter its behavior or use practices when we receive a Do Not Track signal from your browser. available in electronic format on this webpage does not constitute an offer to sell or the these pages, please confirm that you are a medical journalist and that you would like to accredit to only with, relevant persons. Plentiful sunshine. interstate or foreign commerce, or of any facility of a national securities exchange of the United Use the Website to artificially generate traffic or page links to a website or for any other purpose not expressly allowed under these Terms. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. available on the website of the Luxembourg Stock Exchange (www.bourse.lu). Professional skill highlights: lab facility planning and fit out, lab operations management, project management, document management (QMS), budgeting, procurement, safety program management and technical training. As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. NextPoint Therapeutics raises $80 million in Series B financing CAMBRIDGE, Mass. the Market, Pharmaceutical Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Higher wind gusts possible.. we & LEVERKUSEN, Germany-- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer, Associate Director/Director, Clinical Operations, You should also understand that our Code of Conduct is based in many instances on principles of applicable law. Board, Document Download For more information, go to www.bayer.com. for Sustainability COVID19 vaccination required for onsite work; Exemptions for religious or medical reasons should reach out to HR for accommodations. By clicking on the I AGREE button, I certify that I am not located in the United States, Bayer, Meet NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. land, water and energy. Bayer Global R&D expenses before special items amounted to 5.3 billion euros. 40789 Monheim am Rhein A spokesperson for Boston-based NextPoint declined . Learn more about Bayer and the opportunities available. R&D expenses before special items amounted to 5.3 billion euros. Associate Director, NextPoint Therapeutics, Boston, Massachusetts; Health Data Science Leader, Insight Data Science, San Francisco, California; Self-employed, Medical Writer and Editor at CRL MedWrite; Senior Regulatory Specialist at Enable Injections, Inc., Cincinnati, Ohio; Pharmacogenomics Project Manager, Vanderbilt University Medical Center Bayer is committed to driving sustainable development and generating a positive impact with its businesses. (DE), Bayer - NextPoint Therapeutics, a Cambridge, Mass.-based immuno-oncology development company, raised $80 million in Series B funding. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. Science, Our The final prospectus, when published, will be available on the website of NextPoint Therapeutics Reports $80 Million Series B for Novel Immuno NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. OriCell Therapeutics-Committed to developing novel immunotherapies . Headquarters, Costa While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. 50 Bayer United States of America - NextPoint Therapeutics Announces $80 in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where Applicants for the VP, Translational Science should reach out to Ashleigh Cunningham, acunningham@kleinhersh.comour staffing partner atKlein Hersh.